Zacks Research Brokers Increase Earnings Estimates for BMY

Key Points

• Zacks Research raised its FY2026 earnings estimate for Bristol Myers Squibb to $6.85 per share, up from $6.27 and slightly below the $6.95 consensus forecast. The firm also initiated a FY2028 estimate of $5.11 per share.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating expectations of $1.60, while revenue rose 5.7% year over year to $12.97 billion. Management maintained FY2026 EPS guidance of $6.75–$7.00.
• Analyst sentiment remains broadly positive, with MarketBeat reporting a “Moderate Buy” consensus rating and a $66.06 average price target; the stock recently traded at $63.86 and offers a 3.9% dividend yield.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Analysts at Zacks Research increased their FY2026 earnings estimates for shares of Bristol Myers Squibb in a note issued to investors on Thursday, August 13th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $6.85 per share for the year, up from their previous forecast of $6.27. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.95 per share. Zacks Research also issued estimates for Bristol Myers Squibb's FY2028 earnings at $5.11 EPS.

A number of other brokerages have also commented on BMY. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 5th. Guggenheim reiterated a "buy" rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating and a $75.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Trading Up 0.0%

Shares of BMY opened at $63.86 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $68.10. The firm has a market capitalization of $130.45 billion, a PE ratio of 14.07, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The stock's fifty day simple moving average is $59.56 and its 200-day simple moving average is $59.00.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.9%. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Swiss RE Ltd. bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. increased its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Davis Asset Management L.P. acquired a new stake in Bristol Myers Squibb in the second quarter worth $27,000. Finally, Bayban acquired a new stake in Bristol Myers Squibb in the fourth quarter worth $31,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source